Standard BioTools Inc

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Standard BioTools Inc posts strong Q4 results, targets margin improvement

Standard BioTools Inc delivered solid Q4 results with revenue growth and cost reductions. The outlook for 2023 includes flat to moderately higher core revenue, improved margins, and strategic expense management. Challenges in genomics and significant operating expenses require attention for sustained growth.

Standard BioTools Inc reports solid Q1 performance and eyes sustained growth

Standard BioTools Inc's Q1 2023 earnings call highlighted positive financial results, operational improvements, and strategic initiatives aimed at driving profitability. While facing challenges in certain revenue segments, the company's focus on cost reduction and revenue growth positions it well for future success.

Standard BioTools Inc. reports robust Q2 earnings, eyes growth opportunities

Standard BioTools Inc. delivered strong financial results in Q2 2023, with revenue growth and improved margins. The company's strategic priorities include stabilizing the core business, enhancing operating discipline, and leveraging M&A for growth. While challenges exist in managing profitability across segments, opportunities for growth through new products and strategic acquisitions are promising.

Standard BioTools Inc (LAB) reports strong Q3 earnings and advances merger with SomaLogic

Standard BioTools Inc (LAB) delivered robust financial results in Q3 2023, showcasing revenue growth, margin expansion, and operational improvements, setting a positive trajectory for future performance.
The company's strategic initiatives, including the pending merger with SomaLogic, signal a commitment to driving growth, fostering innovation, and enhancing shareholder value in a competitive market landscape.
While facing challenges in margin targets and post-merger integration, Standard BioTools Inc (LAB) remains well-positioned to capitalize on opportunities in biotechnology, expand market reach, and sustain its growth momentum.

Standard BioTools Inc (LAB) posts robust Q4 earnings and outlines growth strategies for 2024

Standard BioTools Inc (LAB) delivered a strong performance in Q4 2023, driven by revenue growth, margin expansion, and cost reduction.
The company's strategic focus on profitability, diversified revenue streams, and operational efficiency sets a solid foundation for future growth.
While facing challenges in cost synergies and margin maintenance, Standard BioTools Inc (LAB) is well-positioned to capitalize on opportunities for revenue growth and operational improvements.

Standard BioTools Inc achieves revenue growth and profitability in Q1

Standard BioTools Inc's Q1 2024 performance reflects steady revenue growth and improved profitability. The company's strategic initiatives and strong financial position with $464 million in cash equivalents provide a solid foundation for future growth and value creation.

Standard BioTools Inc accelerates cost reduction efforts amidst revenue challenges

Standard BioTools Inc's Q2 2024 performance focused on cost reduction, revised revenue guidance, and strategic partnerships for future growth.
The company aims to achieve breakeven adjusted EBITDA by 2026, supported by strong cash position and diversified revenue streams.
Challenges include contract delays in SomaScan services and suspension of share repurchase program, while opportunities lie in strategic M&A and new partnerships.
Overall, Standard BioTools Inc navigates market uncertainties with a focus on financial sustainability and operational efficiency for long-term success.

Standard BioTools Inc reports mixed Q3 results, focuses on growth

Standard BioTools Inc's Q3 performance reflects a mixed revenue picture with strong growth in Consumables but a decline in Instruments business. The company's focus on cost management and strategic initiatives to drive long-term growth and profitability is evident.
Maintaining a robust cash position and emphasizing high-margin consumables position Standard BioTools Inc well for future success. Addressing challenges in the Instruments segment and sustaining cost management are key priorities for the company moving forward.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that it will report fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of the market.

Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024

Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings Increasing access to Imaging Mass Cytometry in pharmaceutical and clinical research settings

Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

Achieving scale with pro forma full year 2023 revenue of approximately $192 million Achieving scale with pro forma full year 2023 revenue of approximately $192 million

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives Establishes Leading Platform of Complementary Multi-omic Technologies with Enhanced Scale and Commercial Reach; Strengthened Balance Sheet to Self-Fund Future Growth Initiatives

Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq: SLGC) at its Special Meeting of Stockholders.

Standard BioTools Stockholders Approve Merger with SomaLogic

SomaLogic

Stockholder Approval Represents Key Milestone Toward Completion of Standard BioTools Transaction Combination Will Create a Diversified Leader in Life Sciences Tools BOULDER, Colo. , Jan. 4, 2024 /PRNewswire/ -- SomaLogic, Inc. (Nasdaq: SLGC) ("the Company"), a leader in proteomics technology, today announced that, based on the preliminary vote count provided by its proxy solicitors following the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. (Nasdaq: LAB) ("Standard BioTools").

SomaLogic Stockholders Vote to Approve Standard BioTools Transaction at Special Meeting

BOSTON--(BUSINESS WIRE)--Boston Millennia Partners (“Boston Millennia”), a significant shareholder of SomaLogic (the “Company”) (Nasdaq: SLGC) today announced that it intends to vote against the Company's planned merger (the “Merger”) with Standard BioTools Inc. (Nasdaq: LAB).

Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued the following statement regarding the proposed merger (the “Proposed Merger” or the “Transaction”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB). We would like to thank the many shareholders and stakeholders who have engaged in a.

Madryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional Disclosures

SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that a second leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that all Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company's upcoming Special Meeting of Stockholders to be held on January 4, 2024.

Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

BOULDER, Colo. , Dec. 28, 2023 /PRNewswire/ -- Dr. Larry Gold, the founder of SomaLogic, Inc. ("SomaLogic" or the "Company") (Nasdaq: SLGC) and Dr. Jason Cleveland, SomaLogic's current Chief Technology Officer, are issuing the below letter to SomaLogic's stockholders regarding their opposition to the Company's proposed merger with Standard BioTools, Inc. ("Standard") (Nasdaq: LAB).

Dr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioTools

CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management (“Tikvah”), a significant shareholder of Somalogic (the “Company”) (Nasdaq: SLGC) with voting rights for 5.9 million shares, or 3.1% of the outstanding shares of Somalogic, today announced that it intends to vote against the Company's proposed merger with Standard BioTools Inc. (Nasdaq: LAB). Tikvah believes the proposed merger is not in the best interest of Somalogic shareholders, echoing reasons elaborated by other investors opposing the mer.

Tikvah Management Announces Intention to Vote against Somalogic's Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn” or “we”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today reiterated its view that there is a viable alternative to the proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (Nasdaq: LAB). Madryn issued the following statement: It is our view that SomaLogic's consider.

Madryn Asset Management Reiterates Alternative Path to SomaLogic's Value-Destructive Proposed Merger with Standard BioTools

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company's upcoming Special Meeting of Stockholders to be held on January 4, 2024. The Company issued the following statement:

ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today commented on the additional disclosures provided late yesterday afternoon by SomaLogic related to its proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard BioTools”) (Nasdaq: LAB). Madryn issued the followi.

Madryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioTools

Believes that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet Iterates that SomaLogic can Thrive as a Standalone Enterprise and Does Not Need Standard BioTools to Thrive Expresses Serious Concerns with Other Aspects of the Proposed Merger, including Potential Conflicts of Interest BALTIMORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Skye Fund III, which together with its affiliates, owns approximately 3.4 million shares of SomaLogic, Inc., (NASDAQ: SLGC) (the “Company”) and has been an investor in the Company for 20 years, today issued an open letter to the Company's shareholders regarding its opposition to the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (NASDAQ: LAB) and its intention to vote AGAINST the Proposed Merger at the upcoming special meeting of shareholders scheduled for January 4, 2024. The full text of the letter is set forth below: December 20, 2023 Dear Fellow Shareholders, Skye Fund III and its affiliates (collectively, “Skye”) own approximately 3.4 million shares of Common Stock, $0.0001 par value, of SomaLogic, Inc. (NASDAQ: SLGC) (“SomaLogic” or the “Company”).

Skye Fund III Issues Letter Regarding Opposition to SomaLogic's Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued a presentation detailing why shareholders should reject the Company's proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard”) (Nasdaq: LAB). Shareholders should visit www.NoSomaLogicMerger.com for Mad.

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

NEW YORK--(BUSINESS WIRE)--Madryn Asset Management, LP (collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued an open letter to fellow shareholders regarding its opposition to the Company's proposed merger (the “Merger” or the “Combination”) with Standard BioTools Inc. (“Standard”) (Nasdaq: LAB). Additionally, Madryn announced it has filed a preliminary proxy stat.

Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transacti.

STANDARD BIOTOOLS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Standard BioTools Inc. - LAB

SOUTH SAN FRANCISCO, Calif. and BOULDER, Colo., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – and SomaLogic, Inc. (Nasdaq: SLGC), a leader in data-driven proteomics technology, today announced that the companies have set a date for their respective Special Meetings of Stockholders in connection with the pending all-stock merger which was previously announced on October 4, 2023.

Standard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger

Standard BioTools Inc. (LAB) Q3 2023 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- BioTools Inc. (“SBI” or the “Company”) (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the third quarter ended September 30, 2023.

Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will give a presentation with a moderated Q&A session at the Jefferies London Healthcare Conference on Wednesday, November 15 at 11:00 a.m. GMT.

Standard BioTools to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close of the market.

Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023

JetBlue Airways

Seelos Therapeutics

The process of buying penny stocks is similar to purchasing any other stock shares. The main difference is penny stocks are often not listed on major exchanges like the NYSE and Nasdaq.

News for Standard BioTools Inc Stock (LAB)